Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Yves Boucher, Ph.D.

Co-Author

This page shows the publications co-authored by Yves Boucher and Dan Duda.
Connection Strength

0.683
  1. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
    View in: PubMed
    Score: 0.149
  2. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.053
  3. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.
    View in: PubMed
    Score: 0.052
  4. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med. 2018 03 14; 10(432).
    View in: PubMed
    Score: 0.049
  5. Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med. 2016 Dec 01; 6(12).
    View in: PubMed
    Score: 0.045
  6. Corrigendum: Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med. 2016 12 01; 6(12).
    View in: PubMed
    Score: 0.045
  7. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med. 2016 10 12; 8(360):360ra135.
    View in: PubMed
    Score: 0.044
  8. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):14325-30.
    View in: PubMed
    Score: 0.041
  9. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012; 7(2):e26331.
    View in: PubMed
    Score: 0.032
  10. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011 Jul; 91(3):1071-121.
    View in: PubMed
    Score: 0.031
  11. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33.
    View in: PubMed
    Score: 0.030
  12. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3020-6.
    View in: PubMed
    Score: 0.026
  13. Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC). J Clin Oncol. 2008 May 20; 26(15_suppl):4096.
    View in: PubMed
    Score: 0.025
  14. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol. 2006 Oct; 33(5 Suppl 10):S35-40.
    View in: PubMed
    Score: 0.022
  15. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.021
  16. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.